ICAD icon

iCAD Inc

1.83 USD
+0.06
3.39%
At close Dec 20, 4:00 PM EST
1 day
3.39%
5 days
-5.18%
1 month
18.06%
3 months
15.82%
6 months
26.21%
Year to date
-0.54%
1 year
10.91%
5 years
-75.76%
10 years
-81.04%
 

About: icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Employees: 69

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

9% more capital invested

Capital invested by funds: $7.45M [Q2] → $8.15M (+$701K) [Q3]

1.98% less ownership

Funds ownership: 21.58% [Q2] → 19.6% (-1.98%) [Q3]

10% less funds holding

Funds holding: 52 [Q2] → 47 (-5) [Q3]

31% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 13

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

78% less call options, than puts

Call options by funds: $8K | Put options by funds: $37K

Research analyst outlook

We haven’t received any recent analyst ratings for ICAD.

Financial journalist opinion

Based on 3 articles about ICAD published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
Neutral
GlobeNewsWire
2 weeks ago
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
Neutral
GlobeNewsWire
3 weeks ago
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
Neutral
Seeking Alpha
1 month ago
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Operator Greetings. Welcome to the iCAD Incorporated Third Quarter 2024 Earnings Call.
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024.
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
Neutral
GlobeNewsWire
1 month ago
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 at the Sheraton New York Times Square Hotel in New York City, New York. Management will be available for one-on-one meetings throughout the day. To request a meeting with iCAD, investors should contact their Craig-Hallum representative.
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
Neutral
Newsfile Corp
2 months ago
iCAD to Participate in the LD Micro Main Event XVII
Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October 29-30, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a company presentation at 10:30 a.m.
iCAD to Participate in the LD Micro Main Event XVII
Neutral
GlobeNewsWire
2 months ago
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France. At JFR, iCAD will premier ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company's advanced AI solutions to healthcare providers worldwide.
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
Neutral
Seeking Alpha
4 months ago
iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Capital Yale Jen - Laidlaw & Company Operator Good day and welcome to the iCAD Incorporated Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024.
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
Charts implemented using Lightweight Charts™